Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.
Neoplasms
DRUG: AZD2171|DRUG: AZD0530
Determine the safety and tolerability of ascending daily oral doses of AZD2171 when co-administered with AZD0530 to patients with advanced solid tumours by assessment of AEs, vital signs, HRCT Scans, clin chem, haematology, urinalysis, ECG and phys exam, assessed at each visit
Pharmacokinetics (PK) of AZD2171 alone and in combination with AZD0530, assessed at each visit|Safety and efficacy, assessed at each visit|Genetic variation of pathways targeted by AZD2171 and AZD0530, assessed during study
The purpose of the study is to determine if the maximum tolerated doses of AZD2171, in combination with AZD0530, in treating patients with advanced solid tumours are safe, tolerable and efficacious.